High‐Efficiency, Prevascularization‐Free Macroencapsulation System for Subcutaneous Transplantation of Pancreatic Islets for Enhanced Diabetes Treatment
Advanced Materials · 2024
DOI: 10.1002/adma.202408329 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2024. Verfasst von Seunggyu Jeon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Ulsan National Institute of Science and Technology, 50, UNIST-gil, Ulju-gun, Ulsan, 44919, South Korea. Hauptthemen laut MEDLINE: Islets of Langerhans Transplantation, Islets of Langerhans, Diabetes Mellitus, Experimental, Alginates. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Trade, Industry & Energy, National Research Foundation of Korea, Korea government.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Pancreatic islet macroencapsulation systems for subcutaneous transplantation have garnered significant attention as a therapy for Type I diabetes due to their minimal invasiveness and low complication rates. However, the low vascular density of subcutaneous tissue threatens the long‐term survival of islets. To address this issue, prevascularized systems are introduced but various challenges remain, including system complexity and vascular‐cell immunogenicity. Here, a novel prevasculature‐free macroencapsulation system designed as a multilayer sheet, which ensures sufficient mass transport even in regions with sparse vasculature, is presented. Islets are localized in top/bottom micro‐shell layers (≈300 µm thick) to maximize proximity to the surrounding host vasculature. These sheets, fabricated via bioprinting using rat islets and alginate‐based bio‐ink, double islet viability and optimize islet density, improving insulin secretion function by 240%. The subcutaneous transplantation of small islet masses (≈250 islet equivalent) into diabetic nude mice enable rapid (120 days. Additionally, antifibrotic drug‐loaded multilayer sheets facilitate blood glucose regulation by rat islets at the subcutaneous sites of diabetic immunocompetent mice for >35 days. Thus, this macroencapsulation system can advance the treatment of Type I diabetes and is also effective for islet xenotransplantation in subcutaneous tissue.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Ulsan National Institute of Science and Technology, 50, UNIST-gil, Ulju-gun, Ulsan, 44919, South Korea.
ORCID-Profile: Hyun-Wook Kang
Förderung
- Ministry of Trade, Industry & Energy
- National Research Foundation of Korea
- Korea government
- Ministry of Trade, Industry and Energy
Zitieren
APA
Jeon, S., Heo, J. H., Myung, N., Shin, J. Y., Kim, M. K., & Kang, H. W. (2024). High‐Efficiency, Prevascularization‐Free Macroencapsulation System for Subcutaneous Transplantation of Pancreatic Islets for Enhanced Diabetes Treatment. Advanced Materials. https://doi.org/10.1002/adma.202408329
Vancouver
Jeon S, Heo JH, Myung N, Shin JY, Kim MK, Kang HW. High‐Efficiency, Prevascularization‐Free Macroencapsulation System for Subcutaneous Transplantation of Pancreatic Islets for Enhanced Diabetes Treatment. Advanced Materials. 2024. doi:10.1002/adma.202408329
BibTeX
@article{Jeon2024,
author = {Jeon, Seunggyu and Heo, Jun-Ho and Myung, Noehyun and Shin, Ji Yeong and Kim, Min Kyeong and Kang, Hyun-Wook},
title = {High‐Efficiency, Prevascularization‐Free Macroencapsulation System for Subcutaneous Transplantation of Pancreatic Islets for Enhanced Diabetes Treatment},
journal = {Advanced Materials},
year = {2024},
doi = {10.1002/adma.202408329}
}
EUVIMED